NVS

Novartis
D

NVS

Arincen80/100B

Novartis cash flow statement 1998–2026

Novartis's free cash flow over the last twelve months was 15.82B USD: operating cash flow of 18.39B USD less 2.57B USD of capital spending. That is 28.1% of its revenue and 8.26 a share.

Operating cash flow Free cash flow

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Jun 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Net income
12.76B14.06B11.94B8.57B6.05B22.91B8.07B7.15B12.61B7.70B6.70B
Depreciation and amortization
5.34B5.35B6.07B8.28B6.71B5.60B6.46B5.83B5.21B4.74B6.04B
Stock-based compensation
—0.001.04B865.00M791.00M700.00M738.00M758.00M759.00M683.00M671.00M
Change in working capital
-2.03B-3.08B-706.00M-369.00M-796.00M-73.00M-291.00M199.00M499.00M244.00M-77.00M
Change in receivables
-672.78M-1.13B-931.00M-1.50B-397.00M-352.00M137.00M-980.00M-569.00M-204.00M-229.00M
Change in inventory
-40.84M34.17M-225.00M-546.00M-560.00M-102.00M-543.00M-382.00M-533.00M-247.00M-235.00M
Change in payables
-194.29M-274.40M-105.00M479.00M-181.00M-111.00M-324.00M553.00M309.00M58.00M-587.00M
Change in other working capital
-1.12B-1.71B555.00M1.20B342.00M492.00M439.00M1.01B1.29B637.00M974.00M
Other non-cash items
792.75M3.27B-2.43B-3.44B359.00M-15.68B-3.14B-2.10B-6.03B-2.04B-2.98B
Operating cash flow
18.39B19.14B17.62B14.46B14.24B15.07B13.65B13.63B14.27B12.62B11.48B
Operating cash flow growth
-11.54%+8.66%+21.86%+1.56%-5.54%+10.41%+0.18%-4.53%+13.08%+9.99%-3.55%
Capital expenditure
-2.57B-1.56B-3.81B-2.75B-2.24B-2.56B-2.59B-2.26B-3.36B-2.75B-2.88B
Acquisitions
-15.65B-3.01B-3.83B-3.57B-864.00M20.46B-9.96B-3.77B-1.07B-755.00M-765.00M
Purchases of investments
-281.13M-304.55M-3.65B-747.00M-34.81B-16.59B-2.13B-530.00M-2.70B-1.05B-777.00M
Sales and maturities of investments
1.19B2.19B3.70B11.60B39.49B2.74B1.22B3.71B639.00M879.00M869.00M
Other investing
-577.14M140.72M-2.38B-624.00M-1.43B-1.34B282.00M-264.00M895.00M551.00M111.00M
Investing cash flow
-17.80B-4.90B-7.51B5.60B1.47B4.21B-13.18B-2.23B-5.59B-3.12B-3.44B
Debt issued (repaid)
16.59B2.72B4.39B-1.94B-2.59B-5.67B7.07B-4.96B4.18B4.10B2.06B
Shares issued
—27.14M0.000.000.000.000.000.000.000.000.00
Share buybacks
-6.85B-9.26B-8.33B-8.72B-10.65B-3.06B-2.84B-5.53B-2.04B-5.49B-1.11B
Dividends paid
-9.02B-7.82B-7.62B-7.26B-7.51B-7.37B-6.99B-6.65B-6.97B-6.50B-6.48B
Other financing
-259.61M-577.95M-177.00M3.63B181.00M-169.00M549.00M3.51B581.00M151.00M215.00M
Financing cash flow
472.20M-14.94B-11.74B-14.28B-20.56B-16.26B-2.21B-13.63B-4.24B-7.73B-5.31B
Net change in cash
960.07M-24.00M-1.93B5.88B-4.89B2.75B-1.45B-2.16B4.41B1.85B2.33B
Free cash flow
15.82B17.59B13.81B11.71B12.00B12.52B11.07B11.37B10.92B9.88B8.60B
Free cash flow growth
-5.87%+27.40%+17.94%-2.43%-4.14%+13.10%-2.67%+4.13%+10.55%+14.88%+6.84%
Free cash flow margin
28.09%32.09%26.69%25.09%27.60%28.46%22.18%23.35%23.68%22.75%17.39%
Free cash flow per share
8.269.006.785.605.465.544.824.904.664.163.58
Free cash flow per share growth
-3.18%+32.62%+21.24%+2.46%-1.39%+14.91%-1.69%+5.25%+11.83%+16.28%+8.53%
Income taxes paid
—0.000.000.000.000.000.000.000.000.000.00

Figures in USD. Free cash flow is operating cash flow less capital expenditure; owner earnings take off only the spending that keeps the business as it is, not the spending to grow it (an estimate by Financial Modeling Prep). Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Novartis's cash flow

Source: Financial Modeling Prep